E5103

Breast
Breast - Male

Indiana University (IU)

• Eskenazi Hospital
• Indiana University Hospital / IU Simon Cancer Center
• Spring Mill Medical Center

• Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?
  Partridge AH;Sepucha K;O'Neill A;Miller KD;Baker E;Dang CT;Northfelt DW;Sledge GW;Schneider BP;
• Quality of Life Following Receipt of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer
  Rosenberg SM;O'Neill A;Sepucha K;Miller KD;Dang CT;Northfelt DW;Sledge GW;Schneider BP;Partridge AH;
• Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
  Sparano J;O'Neill A;Alpaugh K;Wolff AC;Northfelt DW;Dang CT;Sledge GW;Miller KD;
• Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events
  Ip EH;Saldana S;Miller KD;Carlos RC;Gareen IF;Sparano JA;Graham N;Zhao F;Lee JW;O'Connell NS;Cella D;Peipert JD;Gray RJ;Wagner LI;
• Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)
  Miller KD;O'Neill A;Gradishar W;Hobday TJ;Goldstein LJ;Mayer IA;Bloom S;Brufsky AM;Tevaarwerk AJ;Sparano JA;Le-Lindqwister NA;Hendricks CB;Northfelt DW;Dang CT;Sledge GW;